The Role of Methionine in Cancer Growth and Control

Does methionine restriction offer an alternative to caloric restriction in cancer care?

By Tina Kaczor, ND, FABNO

Printer Friendly PagePrinter Friendly Page


Methionine (Met) is 1 of 8 essential amino acids in the human diet, and the only 1 that contains sulfur. It is the requisite substrate for homocysteine, cysteine, taurine, S-adenosyl methionine (SAMe) and polyamines. Methionine is also needed for cellular proliferation, specifically in protein and RNA synthesis. Metabolically, methionine acts as an anabolic stimulant. Restriction of methionine in the diet has been used in animal studies as a mimetic to caloric restriction with similar metabolic effects. Many of these effects, such as lower insulin-like growth factor (IGF), should induce favorable outcomes in patients with a history of cancer. This review explores the theory and evidence for a normal-calorie, methionine-restriction diet in the context of cancer care specifically.


While dubbed essential, methionine is unique among the essential amino acids in that it is the only 1 whose long-term dietary deprivation is still compatible with life.1 Unlike the other essential amino acids, which must be ingested, methionine can be recycled by remethylation of homocysteine in normal cells. There are 2 possible remethylation pathways: 
  1. Homocysteine can be converted to methionine by methionine synthase (MetS) in a methyl-tetrahydrofolate (folate) and methyl-cobalamin (B12) dependent reaction. 
  2. Homocysteine can be remethylated by betaine-homocysteine methyltransferase (BHMT), a reaction requiring trimethylglycine (betaine) as the methyl donor. 
As long as there is homocysteine, intact MetS and/or BHMT, and the requisite cofactors, the production of methionine is possible. This is true for all normally functioning cells. (Figure)
Figure. Methionine Utilization. 
Most cancer cells do not have methionine cycle enzymes intact, though.2 As a result, they need to have methionine available for growth processes. This metabolic difference in methionine usage may allow for a targetable vulnerability in cancer cells. Noncancerous cells should be capable of surviving without methionine, while cancer cells would not. This has been demonstrated in animal models of various cancers.3,4 
Methionine plays a role in many steps within the carcinogenic processes. Methionine is necessary for protein and RNA synthesis in all cells. Another role is as the substrate for S-adenosyl methionine (SAMe), which acts as an essential methyl donor for numerous molecules within cells, including methylation of DNA in the nucleus.5 Global hypomethylation (ie, reduced methylation that is genome-wide) is implicated in various cancers and results in chromosomal instability.6 Hypermethylation of promotor regions of tumor suppressor genes can effectively turn off the expression of those genes. These epigenetic changes of carcinogenesis are influenced by the microenvironment of the tumor, including the availability of methyl groups from the methionine/folate cycle.7,8,9,10 (This review will not include methionine’s role in carcinogenesis per se. Rather the effects of methionine, and its deprivation, on existing cancer are the scope of this review.)
Methionine is needed for the production of polyamines (putrescine, spermidine, spermine), which are involved in cellular division and are found in higher concentration in tumors.11 Polyamines decrease apoptosis, increase proliferation, and are involved in tumorigenesis.12 Their inhibition has been proposed as a means of reducing cancer risk.13 Preliminary trials limiting polyamines (through diet and gut ecology manipulation) in men with metastatic prostate cancer suggest such deprivation may significantly delay cancer-related mortality.14,15 While hypothetical, methionine restriction is expected to result in less polyamine production intracellularly.
A recent study of breast cancer cells found that methionine deprivation reduced growth of tumor-initiating cells (TICs) (ie, the stem cell niche).16 The authors propose that since methionine is required for protein synthesis, its deprivation serves as a block to necessary anabolic processes. The authors conclude, “Our results may also explain the anti-cancer health benefits of caloric restriction, intermittent fasting and the vegetarian diet, by systemically reducing protein synthesis in TICs.” 
There is direct evidence that methionine restriction leads to selective death of cancer cells versus normal cells.
The effect of methionine restriction on whole organisms is such that proliferation and anabolic processes are lessened. In organisms from yeast to mammals, caloric restriction results in inhibition of insulin-like growth factor (IGF) signaling, activation of adenosine monophosphate activated kinase (AMPK), inhibition of mammalian target of rapamycin (mTOR), and reduction in mitochondrial oxidation.17,18,19 Disruption of such anabolic pathways also occurs with diets containing adequate calories that restrict methionine.20,21 IGF, AMPK, and mTOR are well-characterized pathways of cancer growth, making their disruption a desirable goal.22
In vitro, there is direct evidence that methionine restriction leads to selective death of cancer cells versus normal cells.23,24 Various cancer cell types cannot survive in media devoid of methionine even when homocysteine is present.25 Specifically, many cancer cells undergo cell cycle arrest and eventually apoptosis mediated by pro-apoptotic molecules such as Bcl-2.26 In addition, nutrient-sensing mechanisms within cells have been proposed as a means of organism control of weakened or defective cells. When certain nutrients, including methionine, are scarce, autophagy may ensue. 27
Ample animal evidence suggests that methionine restriction may affect the growth and/or metastasis of cancers. Methionine restriction in rodents has led to tumor regression in xenografts of prostate cancer.28,29 Sarcoma-bearing nude mice deprived of methionine showed longer survival and regression of tumors.28 Rodents with implanted brain tumor xenografts achieved stability or regression with methionine restriction. Methionine restriction has also lessened metastatic spread of sarcoma tumors in mice.30 Lastly, methionine restriction has demonstrated a potentiation of chemotherapy in mice with implanted brain tumors.31
Ongoing research continues to define effects of methionine deprivation on cancer cells. Cellular disruption of methylation, protein synthesis and intracellular signaling pathways normally stimulated by growth factors such as IGF and mTOR have all been demonstrated.32 The net effect is a reduction of proliferation. While this data is fairly consistent in cell culture and animal models, the translation to humans is much more complicated. Methionine is an essential amino acid. As such, ramifications of its restriction must be weighed against any benefits. 

Methionine Restriction Trials

A handful of phase I studies have assessed the safety and feasibility of iso-caloric diets with methionine restriction in patients with cancer. While the diets have resulted in weight loss, methionine restriction has been generally well tolerated and has not resulted in any nutritional deficiencies. Long-term use and follow up of methionine-restricted diets in patients with cancer or a history of cancer have not yet been the subject of clinical trials. 
Methionine restriction may complement chemotherapies targeting the methionine/folate cycle specifically. In 1995, 14 patients awaiting surgical resection of gastric cancer were given continuous infusion of 5-fluorouracil (5-FU) for 1 week before surgery. All participants also received total parenteral nutrition (TPN) for that week, with half (n=7) given TPN without sulfur-containing amino acids (methionine and cysteine).33 After resection, only those receiving sulfur-free TPN had histologic cancer cell degeneration and better thymidylate synthase inhibition (ie, the mechanism of 5-FU). This trial suggests possible synergy with 5-FU and is the only trial in which TPN was used, providing complete control over nutrient intake and the ability to achieve no methionine ingestion at all. 
In 2002, Epner and colleagues published a phase I study of 8 people with metastatic cancer and concluded that methionine restricted diets are feasible and well tolerated over the short/medium term. Restriction entailed prescribed diets using a commercial methionine-free amino acid blend (Hominex-2, Abbott Labs) as the primary protein source. The diet contained 0.6-0.8 g of total protein, 25-35 kcal, and 2 mg of methionine per kilogram of body weight per day. Participants remained on the experimental diet for 8-39 weeks (mean=17.3 weeks). Circulating methionine was reduced an average of 58% (from 21.6 +/- 7.3 µm to 9 +/- 4 µm) within 2 weeks of start of treatment. Homocysteine was lowered only slightly. Serum albumin levels remained stable or increased. Daily protein targets were met and overall caloric energy intake increased. The only side effect was weight loss of approximately 0.5% of BMI weekly.34
In a follow-up publication, Epner commented on this phase I trial stating that 1 patient with hormone-independent prostate cancer experienced a 25% reduction in PSA after 12 weeks on the trial.35 Another patient with progressive renal cell carcinoma had a radiographic objective response to treatment. While these results were incidental to the design of this phase I trial, they are intriguing.
A single day of a methionine-restricted diet appears to lower circulating levels of methionine dramatically. A 2008 phase I study looked at methionine restriction alongside the chemotherapy drug cystemustine in patients with metastatic melanoma or glioma.36 The study assessed circulating methionine after 1, 2, 3, and 4 days of methionine-restricted diet. After day 1, study participants experienced an average 41% reduction in circulating methionine without appreciable further lessening in the ensuing days. 
Based on the phase I finding, the same researchers designed a phase II trial to assess the safety and efficacy (toxicity and nutritional status) of cystemustine with 1 day of methionine restriction before each biweekly treatment.37 Twenty patients with metastatic melanoma and 2 with glioma received an average of 4 cycles of cystemustine. While toxicity of treatment did not change and nutritional status was preserved, the outcomes were not impressive. The patients experienced no improvement in disease-free survival (median=1.8 months) nor overall survival (median=4.6 months). The authors point out that the patients recruited had very poor prognosis and/or were heavily pretreated. One patient had 27 months of stable disease. 
Compliance with a methionine restriction diet, even short term, may be a challenge. In a publication in 2010, 11 patients undergoing combination chemotherapy FOLFOX (5-FU, leucovorin, oxaliplatin) over a 48-hour period underwent methionine deprivation diet for 3 days around treatment.38 Methionine levels fell an average 58% by day 1. Only 4 patients were evaluable at the end of treatment due to difficulty in adhering to the methionine restriction diet. Of these 4, 3 had partial responses to FOLFOX and 1 had stable disease.
These phase I/II trials demonstrate that methionine restriction is feasible short term. The 2010 study suggests instituting a low-methionine diet may be difficult for patients, at least if done without the use of a supplemental low-methionine meal-replacement product. As several of the studies demonstrated, weight loss is also very likely, even if the diet contains adequate calories. These are very practical hurdles that may limit the utility of methionine restriction diets clinically.

Methioninase Agents in Development

Given the compliance challenges, an ideal solution would be to remove methionine from cells, rendering them deficient in methionine without requiring dietary deprivation. Methioninase derivatives using recombinant DNA (rDNA) derived from bacteria are in development.39 Because of the concerns about the antigenicity of rDNA methioninase directly infused into the bloodstream, less antigenic conjugates and liposomes are also being researched.40,41 Overall, methioninase agents are promising in their low toxicity and serve as another means of deducing response to a low-methionine environment. 
In 1996, Hoffman and colleagues published the first phase I trial of intravenous methioninase derived from Pseudomonas putida in 3 patients with metastatic breast cancer.42 Each woman received a different dose: The first 2 received 5,000 units or 10,000 units over 2 hours, and the third woman received 20,000 units over 10 hours. Depletion of serum methionine began within 30 minutes of infusion. Serum methionine was reduced by 35% and 19% in the first 2 patients and reached a 200-fold reduction (from 23.1 µm to 0.1 µm) in the third patient. None of the patients experienced toxicity. This pilot phase I trial established safety and tolerability. Disease outcome measures were not reported. 
A year later, Hoffman and colleagues again published a study on direct infusion of the same rDNA methioninase in patients with breast, lung, or renal cancer or lymphoma. They confirmed that a 6-24 hour infusion of doses ranging from 5,000-20,000 units had no toxicity in late-stage cancer patients.43 The reduction of methionine was as low as 0.1% of baseline. In a 2015 paper looking back at the “40 year odyssey” of methionine research, Hoffman proposed the most strategic use of methioninases might be in conjunction with certain chemotherapeutics.44 Methioninases arrest cancer cells in the S/G2 phase of the cell cycle. Combining chemotherapeutic agents that also target this stage may result in a synergistic effect. This sequential use of using methioninases to arrest the cancer cells and giving a cell cycle–specific cytoxic agent has demonstrated some efficacy in vitro, particularly with paclitaxel.45, 46,47
There is a caveat to the cell cycle arrest from rDNA methioninase. Some in vitro research indicates that the phase of the cell cycle that cells are arrested in is different with methionine deprivation versus methioninase application. Methionine-deprived prostate cancer cells (PC-3) were arrested in the G2/M phase, while methioninase arrested the cell cycle at the S/G2 phase.48 This differentiation may influence whether there is synergy or antagonism with a given chemotherapeutic.


Caloric restriction results in increased longevity across various species, including flies, fish, and dogs.49,50,51 Within oncology, caloric restriction has demonstrated decreased side effects of chemotherapy treatments.52,53 Excess energy balance, such as a diabetic state and obesity, are implicated in poorer outcomes in those with a history of cancer.54,55,56 Caloric restriction is a feasible option for those who are overweight or obese, at least until normal weight is achieved. However, long-term caloric restriction may result in nutrient deficiencies that influence bone health, immune function, or sarcopenia.57 Methionine restriction may offer a means of achieving similar physiological effects with less severe caloric restriction and higher nutrient intake.
Methionine occurs in all proteins in nature, to some extent. Overall, methionine is generally highest in fish, beef, dairy, eggs, nuts, seeds, and grains, respectively, when looked at on a mg per serving basis.58 Vegetables and fruits have the lowest content of methionine due to lower protein amounts. As a percentage of protein content, nuts tend to have the highest percent concentration (mg methionine/gram protein); however, since animal sources have more protein per serving, the content of methionine is higher for practical purposes. Thus, a vegan diet is fairly low in methionine. It does not, however, reach methionine restriction levels used in the studies mentioned above (2 mg methionine/kg body weight/day). 
Whether humans are able to arrest cancerous growth with methionine restriction, as established in animals, is not known. There are no prospective trials of methionine restriction designed to measure outcome in cancer survivors. While speculative, methionine restriction does result in effects expected to have physiological benefit for those with a history of cancer. These effects include lessening of IGF-1 production, improved insulin sensitivity of normal cells,59 increased fat oxidation,60 and lessening of inflammation overall.61
A low-methionine therapeutic diet has been established for people with inborn errors of metabolism of the methionine cycle. The most common of these errors is cystathionine beta synthase (CBS) deficiency,62 the enzyme needed to commit homocysteine to the transulfuration pathway toward cysteine. The effect of a defect in CBS is a backup of methionine and homocysteine in the blood. Therapeutically, those affected by CBS must be put on a low-protein/low-methionine diet. Since all food in nature that contains protein has methionine, specially formulated medical food products have been created with only trace amounts of methionine to serve as the primary protein source for those with CBS.63 These medical foods were used to achieve the ultra-low levels of methionine in several of the phase I studies discussed above.
The requisite amount of methionine for human health appears to be approximately 13 mg/kg body weight/day.64 Many of the methionine-deficient diets used in the clinical trials contained 2 mg/kg body weight/day of methionine and 0.6-0.8 g/kg body weight/day of overall protein in the diet. Long-term effects of this restriction have not been addressed. It is presumed that 0.5% of BMI loss per week (as reported in phase I trials) is likely. Methionine restriction appears to effectively lower visceral adiposity,65 which is desirable in those with cancer, but muscle loss can be a risk as well. Muscle degradation limit immune function, as the body will prioritize muscle preservation over immunity at some point in an ongoing sarcopenic state.66,67
While calorie- or methionine-restrictive diets appear to increase longevity across species, at least 1 rodent study suggests that reproductive function is best with a more protein-rich diet.68 Looking at ratios of macronutrients, longevity in male and female rats was optimal at protein:carbohydrate (P:C) ratios of 1:13 in male rats and 1:11 in female rats. Reproductive health was optimal at 1:1 ratio for both genders. The practical impact of this, even if it holds true in humans, is limited only to those considering conception. This is pertinent only to a relative small number of patients with cancer.
The rodent studies are consistent regarding increased longevity. However, human data is more complicated regarding protein intake specifically. An intriguing study published in 2014 suggested stratification of the effects of protein intake by both age and food source. Dietary intake of 6,381 adults ages 50 and over (average age 65) from NHANES III was divided into high protein (20% or more of calories from proteins), moderate protein (10-19%) or low protein groups (<10% of calories from protein).69 High protein intake was associated with increased diabetes mortality across all ages. In those 50-65 years old, high protein intake had a 74% (HR: 1.74; 95% CI: 1.02–2.97) increase in all-cause mortality and a 4-fold (HR: 4.33; 95% CI: 1.96-9.56) increase in cancer death risk during the following 18 years. When the percent of calories from protein was controlled for by type of protein (animal or plant), only animal protein was associated with the apparent detrimental effects of a high-protein diet. Moderate protein consumers (age 50-65) had a 3-fold increase risk of cancer (HR: 3.06; 95% CI: 1.49-6.25). These effects were slightly mitigated in those who consumed plant protein over animal protein. Interestingly, high protein intake for those over 65 years old was associated with reduced cancer and overall mortality. The authors conclude that the detrimental effects of muscle wasting through low protein in the elderly may outweigh other metabolic effects. The concept of higher protein needs (1.0-1.2g/kg body weight/day) in the elderly (>65 years old) is supported by a 2014 consensus report of the European Society for Clinical Nutrition and Metabolism.70
Sufficient research exists regarding bone health in postmenopausal women to remain cautious of protein restriction in this population as well. The anabolic pathways involved in bone growth include mTOR and IGF-1; stimulation of these pathways in bone is desirable. This is precisely the opposite of the mechanisms behind longevity and cancer growth interference. In addition, muscle mass is more apt to degrade with age; preservation is stimulatory for bone growth and improves balance, leading to fewer falls. Given the clinical implications of protein deprivation, caution should be used in elderly women. In general, the protein recommendation for postmenopausal women with osteoporosis/osteopenia is 1.0-1.2 g/kg body weight/day.71
These considerations must be weighed against the clinical utility of anything at our disposal that can slow, stabilize, or even regress cancers in our patients with poor prognoses. Diets high in vegetables/legumes/grains and fruits (>two-thirds of the diet being plant-based) are well evidenced as the best diet for prevention of cancer.72,73 To what extent a high plant-based diet influences outcomes once cancer is present is a subject of ongoing debate, with a less obvious conclusion.74, 75,76,77,78
It should be noted that there is some evidence that ketogenic diets may improve outcome in metastatic cancer patients.79 A true ketogenic diet requires restriction not only of carbohydrates, but of protein as well, as both are capable of increasing circulating glucose. The mechanism behind any benefit to the ketogenic diet in lessening cancer progression may be due to inadvertent methionine restriction.80 Ongoing research should clarify this; high-fat diets using adequate protein (Atkins diet) and restricting carbohydrates only have been studied.81
There is no outcome data on methionine restriction diets specifically used as an intervention in patients with cancers. For practical purposes, vegan diets, with their lower levels of methionine, are a feasible option. Vegans can meet their protein needs while minimizing methionine when compared to an omnivore diet. In addition, large quantities of vegetables, fruits, and legumes are required to meet caloric needs. As long as the diet relies on whole foods, a vegan diet can increase nutrient intake, minimize methionine, and displace less nourishing foods.82
In practice, we must meet each patient where he/she is. The patient’s psychology around food, current body composition, current state of health/disease, finances, time available to prepare food, and beliefs about food are all considerations. Ultimately, creating excess stress through dietary goals that are not attainable may be more harmful than finding a diet that can be both enjoyable and advantageous to health and longevity.83


Methionine restriction diets have been used as a substitute for caloric restriction in animal models and result in similar physiological changes. Given the methionine dependence of various cancer cells, methionine-restricted diets are an intriguing option for those with a history of cancer. While long-term caloric restriction poses the risk of decreasing weight to a detrimental extent,84 methionine restriction without calorie restriction may confer the same benefits while lessening this risk.85 Much more research needs to be done to clarify whether there is indeed benefit to methionine restriction, and if so, which cancer types would be helped and how much restriction is sufficient.

About the Author

Tina Kaczor, ND, FABNO, is editor-in-chief of Natural Medicine Journal and a naturopathic physician, board certified in naturopathic oncology. She received her naturopathic doctorate from National University of Natural Medicine, and completed her residency in naturopathic oncology at Cancer Treatment Centers of America, Tulsa, Oklahoma. Kaczor received undergraduate degrees from the State University of New York at Buffalo. She is the past president and treasurer of the Oncology Association of Naturopathic Physicians and secretary of the American Board of Naturopathic Oncology. She has been published in several peer-reviewed journals. Kaczor is based in Portland, Oregon.


  1. Sugimura T, Birnbaum SM, Winitz M, Greenstein JP. Quantitative nutritional studies with water-soluble, chemically defined diets. VIII. The forced feeding of diets each lacking in one essential amino acid. Arch Biochem Biophys. 1959;81(2):448-455.
  2. Cavuoto P, Fenech MF. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev. 2012;38(6):726-736. 
  3. Kokkinakis DM1, Liu X, Chada S, et al. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res. 2004;64(20):7513-7525.
  4. Cellarier E, Durando X, Vasson MP, et al. Methionine dependency and cancer treatment. Cancer Treat Rev. 2003;29(6):489-499.
  5. Venkatachalam KV. Novel cancer therapy: targeting methionine metabolism. The FASEB Journal. 2015;29(1s):897.32.
  6. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001;134(7):573-586.
  7. Hoffman RM. Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta. 1984;738(1-2):49-87.
  8. Counts JL1, Sarmiento JI, Harbison ML, Downing JC, McClain RM, Goodman JL. Cell proliferation and global methylation status changes in mouse liver after phenobarbital and/or choline-devoid, methionine-deficient diet administration. Carcinogenesis. 1996;17(6):1251-1257.
  9. Choi SW1, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr. 2000;130(2):129-132.
  10. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med (Maywood). 2004;229(10):988-995.
  11. Nishioka, Kenji. Polyamines in Cancer: Basic Mechanisms and Clinical Approaches. Landes Bioscience, 1996.
  12. Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004;4(10):781-792.
  13. Babbar N, Gerner EW. Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res. 2011;188:49-64. 
  14. Cipolla B, Guillí F, Moulinoux JP. Polyamine-reduced diet in metastatic hormone-refractory prostate cancer (HRPC) patients. Biochem Soc Trans. 2003;31(2):384-387.
  15. Cipolla BG, Havouis R, Moulinoux JP. Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. Biomed Pharmacother. 2010;64(5):363-368. 
  16. Lamb R, Harrison H, Smith DL, et al. Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. Oncotarget. 2015;6(7):4585-4601.
  17. Santos J, Leitão-Correia F, Sousa MJ, Leão C. Dietary restriction and nutrient balance in aging. Oxid Med Cell Longev. 2015. Epub ahead of print.
  18. Speakman JR, Mitchell SE. Caloric restriction. Mol Aspects Med. 2011;32(3):159-221. 
  19. López-Torres M, Barja G. Lowered methionine ingestion as responsible for the decrease in rodent mitochondrial oxidative stress in protein and dietary restriction possible implications for humans. Biochim Biophys Acta. 2008;1780(11):1337-1347.
  20. McCarty MF, Barroso-Aranda J, Contreras F. The low-methionine content of vegan diets may make methionine restriction feasible as a life extension strategy. Med Hypotheses. 2009;72(2):125-128. 
  21. Caro P, Gómez J, López-Torres M, et al. Forty percent and eighty percent methionine restriction decrease mitochondrial ROS generation and oxidative stress in rat liver. Biogerontology. 2008;9(3):183-196.
  22. Luo Z1, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci. 2005;26(2):69-76.
  23. Breillout F, Antoine E, Poupon MF. Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst. 1990;82(20):1628-1632.
  24. Fu YM, Yu ZX, Li YQ, et al. Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells. Nutr Cancer. 2003;45(1):60-73.
  25. Pavillard V, Drbal AA, Swaine DJ, Phillips RM, Double JA, Nicolaou A. Biochem Pharmacol. Analysis of cell-cycle kinetics and sulfur amino acid metabolism in methionine-dependent tumor cell lines; the effect of homocysteine supplementation. Biochem Pharmacol. 2004;67(8):1587-1599.
  26. Lu S, Hoestje SM, Choo E, Epner DE. Induction of caspase-dependent and -independent apoptosis in response to methionine restriction. Int J Oncol. 2003;22(2):415-420.
  27. Madeo F, Zimmermann A, Maiuri MC, Kroemer G. Essential role for autophagy in life span extension. J Clin Invest. 2015;125(1):85-93. 
  28. Guo H, Lishko VK, Herrera H, Groce A, Kubota T, Hoffman RM. Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res. 1993;53(23):5676-5679.
  29. Poirson-Bichat F, Gonfalone G, Bras-Gonçalves RA, Dutrillaux B, Poupon MF. Growth of methionine-dependent human prostate cancer (PC-3) is inhibited by ethionine combined with methionine starvation. Br J Cancer. 1997;75(11):1605-1612.
  30. Breillout F, Hadida F, Echinard-Garin P, Lascaux V, Poupon MF. Decreased rat rhabdomyosarcoma pulmonary metastases in response to a low methionine diet. Anticancer Res. 1987;7(4B):861-867.
  31. Kokkinakis DM, Hoffman RM, Frenkel EP, et al. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res. 2001;61(10):4017-4023.
  32. Strekalova E, Malin D, Good DM, Cryns VL. Methionine deprivation induces a targetable vulnerability in triple-negative breast cancer cells by enhancing TRAIL receptor-2 expression. Clin Cancer Res. 2015;21(12):2780-2791. 
  33. Goseki N, Yamazaki S, Shimojyu K, et al. Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial. Jpn J Cancer Res. 1995;86(5):484-489.
  34. Epner DE, Morrow S, Wilcox M, Houghton JL. Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction. Nutr Cancer. 2002;42(2):158-166.
  35. Epner DE. Can dietary methionine restriction increase the effectiveness of chemotherapy in treatment of advanced cancer? J Am Coll Nutr. 2001;20(5 Suppl):443S-449S; discussion 473S-475S.
  36. Durando X, Thivat E, Farges MC, et al. Optimal methionine-free diet duration for nitrourea treatment: a Phase I clinical trial. Nutr Cancer. 2008;60(1):23-30. 
  37. Thivat E, Farges MC, Bacin F, et al. Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma. Anticancer Res. 2009;29(12):5235-5240.
  38. Durando X, Farges MC, Buc E, et al. Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal cancer: a feasibility study. Oncology. 2010;78(3-4):205-209. 
  39. Yagi S, Yang Z, Li S, Sun X, Tan Y, inventors; Anticancer, Inc., assignee. US patent application 14/162,655. Filed January 23, 2014.
  40. Tan Y, Xu M, Hoffman RM. Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells In Vitro. Anticancer Res. 2010;30(4):1041-1046.
  41. Agrawal V, Alpini SE, Stone EM, Frenkel EP, Frankel AE. Targeting methionine auxotrophy in cancer: discovery & exploration. Expert Opin Biol Ther. 2012;12(1):53-61. 
  42. Tan Y, Zavala J Sr, Xu M, Zavala J Jr, Hoffman RM. Serum methionine depletion without side effects by methioninase in metastatic breast cancer patients. Anticancer Res. 1996;16(6C):3937-3942.
  43. Tan Y, Zavala J Sr, Han Q, et al. Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients. Anticancer Res. 1997;17(5B):3857-3860.
  44. Hoffman RM. Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther. 2015;15(1):21-31.
  45. Yano, S., et al. "Abstract P4-07-04: Methioninase cell-cycle synchronization potentiates chemotherapy for breast cancer." Cancer Research 72.24 Supplement (2012): P4-07.
  46. Pavillard V, Nicolaou A, Double JA, Phillips RM. Methionine dependence of tumours: a biochemical strategy for optimizing paclitaxel chemosensitivity in vitro. Biochem Pharmacol. 2006;71(6):772-778. 
  47. Yano S, Li S, Han Q, et al. Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity. Oncotarget. 2014;5(18):8729-8736.
  48. Hoffman RM. Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther. 2015;15(1):21-31.
  49. Min KJ, Flatt T, Kulaots I, Tatar M. Counting calories in Drosophila diet restriction. Exp Gerontol. 2007;42(3):247-251. 
  50. Comfort A. Effect of delayed and resumed growth on the longevity of a fish (lebistes reticulatus, peters) in captivity. Gerontologia. 1963;49:150-155.
  51. Lawler DF, Larson BT, Ballam JM, et al. Diet restriction and ageing in the dog: major observations over two decades. Br J Nutr. 2008;99(4):793-805.
  52. Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD. Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010;9(22):4474-4476. 
  53. Safdie FM, Dorff T, Quinn D, et al. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009;1(12):988-1007.
  54. Sinicrope FA, Dannenberg AJ. Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol. 2011;29(1):4-7.
  55. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22(3):439-45. 
  56. Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat. 2014;146(1):189-197.
  57. Solon-Biet SM, Mitchell SJ, de Cabo R, Raubenheimer D, Le Couteur DG, Simpson SJ. Macronutrients and caloric intake in health and longevity. J Endocrinol. 2015;226(1):R17-28. 
  58. United States Department of Agriculture: Agricultural Research Service. National nutrient database for standard reference release 28. Accessed October 19, 2015. 
  59. Stone KP, Wanders D, Orgeron M, Cortez CC, Gettys TW. Mechanisms of increased in vivo insulin sensitivity by dietary methionine restriction in mice. Diabetes. 2014;63(11):3721-3733. 
  60. Plaisance EP, Greenway FL, Boudreau A, et al. Dietary methionine restriction increases fat oxidation in obese adults with metabolic syndrome. J Clin Endocrinol Metab. 2011;96(5):E836-840. 
  61. Wanders D, Ghosh S, Stone KP, Van NT, Gettys TW. Transcriptional impact of dietary methionine restriction on systemic inflammation: relevance to biomarkers of metabolic disease during aging. Biofactors. 2014;40(1):13-26. 
  62. Homocysinuria. National Institutes for Health website. Last Reviewed July 2011. Accessed September 20, 2015.
  63. Hominex-2. Amino Acid Modified Medical Food. Abbott Nutrition: For Healthcare Professionals.  Accessed September 20, 2015.  
  64. Raguso CA, Pereira P, Young VR. A tracer investigation of obligatory oxidative amino acid losses in healthy, young adults. Am J Clin Nutr. 1999;70(4):474-483.
  65. Elshorbagy AK, Valdivia-Garcia M, Mattocks DA, et al. Cysteine supplementation reverses methionine restriction effects on rat adiposity: significance of stearoyl-coenzyme A desaturase. J Lipid Res. 2011;52(1):104-112. 
  66. Cosquéric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S. Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr. 2006 Nov;96(5):895-901.
  67. Walrand S, Guillet C, Salles J, Cano N, Boirie Y. Physiopathological mechanism of sarcopenia. Clin Geriatr Med. 2011;27(3):365-385.
  68. Solon-Biet SM, Walters KA, Simanainen UK, et al. Macronutrient balance, reproductive function, and lifespan in aging mice. Proc Natl Acad Sci U S A. 2015;112(11):3481-3486. 
  69. Levine ME, Suarez JA, Brandhorst S, et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab. 2014;19(3):407-417.
  70. Deutz NE, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33(6):929-936. 
  71. Rizzoli R, Stevenson JC, Bauer JM, et al. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas. 2014;79(1):122-132.
  72. Diet: what we eat. American Institute for Cancer Research. Updated December 16, 2014. Accessed September 21, 2015.
  73. Lanou AJ, Svenson B. Reduced cancer risk in vegetarians: an analysis of recent reports. Cancer Manag Res. 2010;3:1-8. 
  74. Saxe GA, Major JM, Westerberg L, Khandrika S, Downs TM. Biological mediators of effect of diet and stress reduction on prostate cancer. Integr Cancer Ther. 2008;7(3):130-138. 
  75. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA. 2007;298(3):289-298.
  76. Kwan ML, Weltzien E, Kushi LH, Castillo A, Slattery ML, Caan BJ. Dietary patterns and breast cancer recurrence and survival among women with early-stage breast cancer. J Clin Oncol. 2009 Feb 20;27(6):919-926. 
  77. Meyerhardt, Jeffrey A., et al. "Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer." Jama 298.7 (2007): 754-764.
  78. Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011;105 Suppl 1:S52-73. 
  79. Fine EJ, Segal-Isaacson CJ, Feinman RD, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition. 2012;28(10):1028-1035. 
  80. Pissios P, Hong S, Kennedy AR, Prasad D, Liu FF, Maratos-Flier E. Methionine and choline regulate the metabolic phenotype of a ketogenic diet. Mol Metab. 2013;2(3):306-313. 
  81. Tan-Shalaby J, Seyfried T. Ketogenic diet in advanced cancer: a pilot feasibility and safety trial in the Veterans Affairs cancer patient population. J Clin Trials. 2013;3:149. 
  82. Dewell A, Weidner G, Sumner MD, Chi CS, Ornish D. A very-low-fat vegan diet increases intake of protective dietary factors and decreases intake of pathogenic dietary factors. J Am Diet Assoc. 2008;108(2):347-356.
  83. Andrews ZB, Abizaid A. Neuroendocrine mechanisms that connect feeding behavior and stress. Front Neurosci. 2014;8:312. 
  84. Imai S. SIRT1 and caloric restriction: an insight into possible trade-offs between robustness and frailty. Curr Opin Clin Nutr Metab Care. 2009;12(4):350-356.
  85. Solon-Biet SM, Mitchell SJ, Coogan SC, et al. Dietary protein to carbohydrate ratio and caloric restriction: comparing metabolic outcomes in mice. Cell Rep. 2015;11(10):1529-1534.